Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 10/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 10/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.38 |
| ▸ | CTSA | P10619 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7494636 | 1.00 | KEAP1 (0.41) | KEAP1NFE2L2MEN1LMNAMAPT | |
| SCHEMBL6139499 | 0.88 | EPHX2 (0.39) | KEAP1NFE2L2MEN1LMNAMAPT | |
| SCHEMBL5673248 | 0.82 | KMT2A (0.41) | LMNAKMT2ASMN1; SMN2CASP1 | |
| SCHEMBL5672253 | 0.82 | KMT2A (0.41) | LMNAKMT2ASMN1; SMN2CASP1 | |
| SCHEMBL5671763 | 0.80 | ENPP3 (0.43) | EPHX2 | |
| SCHEMBL7493489 | 0.80 | ENPP3 (0.43) | EPHX2 | |
| SCHEMBL5672285 | 0.79 | TDP1 (0.40) | MEN1LMNAKMT2ACASP1 | |
| SCHEMBL7495927 | 0.79 | TDP1 (0.40) | MEN1LMNAKMT2ACASP1 | |
| SCHEMBL5670961 | 0.79 | FABP4 (0.41) | MEN1LMNAKMT2ACASP1 | |
| SCHEMBL7490542 | 0.76 | TDP1 (0.43) | KEAP1NFE2L2MEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030208077-A1 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | SANOFI (FR) | 2003-11-06 | — | — | US | claimed |
| EP-0988292-B1 | PIPERAZINE DERIVATIVES AND THEIR USE AS ANTI-INFLAMMATORY AGENTS | SCHERING AG (DE) | 2003-02-12 | — | — | EP | claimed |
| EP-1021449-B1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI SYNTHELABO (FR) | 2002-01-02 | — | — | EP | claimed |
| EP-1021449-A1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2000-07-26 | — | — | EP | claimed |
| WO-1999018110-A1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 1999-04-15 | — | — | WO | claimed |
| US-7153969-B2 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | SANOFI-AVENTIS (FR) | 2006-12-26 | — | — | US | disclosed |
| US-6894186-B2 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | SANOFI-SYNTHELABO (FR) | 2005-05-17 | — | — | US | disclosed |
| US-20040260110-A1 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | SANOFI (FR) | 2004-12-23 | — | — | US | disclosed |
| US-20030208077-A1 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | SANOFI (FR) | 2003-11-06 | — | — | US | disclosed |
| US-6573381-B1 | Useful as intermediates, notably for the synthesis of methyl (S)-2(2-chlorophenyl)-2(4,5,6,7-tetrahydrothieno(3,2-c)-5-pyridyl)acetate or clopidrogel | SANOFI-SYNTHELABO (FR) | 2003-06-03 | — | — | US | disclosed |
| EP-1021449-B1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI SYNTHELABO (FR) | 2002-01-02 | — | — | EP | disclosed |
| EP-1021449-A1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999018110-A1 | HYDROXYACETIC ESTER DERIVATIVES, PREPARATION METHOD AND USE AS SYNTHESIS INTERMEDIATES | SANOFI-SYNTHELABO (FR) | 1999-04-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030208077-A1 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | HAAO, HTR3C, HTR3A | KEAP1 3856/4885NFE2L2 3446/4885MEN1 2274/4885 |
| US-20040260110-A1 | Hydroxyacetic ester derivatives, preparation method and use as synthesis intermediates | HAAO, HTR3C, HTR3A | KEAP1 3856/4885NFE2L2 3446/4885MEN1 2274/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.